Compare NTCT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | HRMY |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1999 | 2020 |
| Metric | NTCT | HRMY |
|---|---|---|
| Price | $32.16 | $27.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $31.00 | ★ $46.70 |
| AVG Volume (30 Days) | 494.1K | ★ 604.0K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | 1.06 | ★ 2.71 |
| Revenue | ★ $891,820,000.00 | $868,453,000.00 |
| Revenue This Year | $6.02 | $19.75 |
| Revenue Next Year | $2.55 | $12.88 |
| P/E Ratio | $30.49 | ★ $10.32 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $18.12 | $25.52 |
| 52 Week High | $33.01 | $40.87 |
| Indicator | NTCT | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 42.06 |
| Support Level | $26.16 | $27.66 |
| Resistance Level | N/A | $28.99 |
| Average True Range (ATR) | 0.92 | 0.77 |
| MACD | 0.04 | 0.29 |
| Stochastic Oscillator | 74.53 | 55.04 |
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.